Scientists finally discover which prostate cancers are life-threatening

November 19, 2013, Cancer Research UK

Cancer Research UK scientists have discovered that the presence of a specific protein can distinguish between prostate cancers that are aggressive and need further treatment from those that may never seriously harm the patient.

The study, published in Oncogene today, found much higher levels of the protein, NAALADL2, in prostate cancer tissue compared with healthy tissue. The difference was especially marked in aggressive prostate cancer tumours and cancer cells that had already spread around the body.

The team confirmed in two independent patient groups that the protein could be used to diagnose prostate cancer. But, even more importantly, it found that high levels of the protein could potentially pinpoint those with aggressive disease who would need surgery, chemotherapy and radiotherapy. Patients with lower levels of the protein were more likely to need monitoring rather than treatment.

After years of trying to unlock the secret of which are life-threatening – sometimes referred to as 'tigers', and which are essentially harmless 'pussycats', this new discovery could revolutionise how doctors treat the disease.

The NAALADL2 causes to behave more aggressively, making them more likely to move and invade healthy tissue surrounding the tumour.

Lead author, Dr Hayley Whitaker, Cancer Research UK scientist at the University of Cambridge, said: "This is early research, but if clinical trials confirm our results then it could help clinicians to tell which patients have a more aggressive tumour and need proportionally aggressive treatment, while sparing patients with low grade tumours a unnecessary radiotherapy or surgery.

"This is an important step along the path to developing a much-sought after test that could distinguish between different types of prostate cancer."

Around 41,000 men per year are diagnosed with prostate cancer in the UK and around 10,700 men die from the disease annually.

There are a number of diagnostic tests available for the disease. The best known is the Prostate Specific Antigen Test (PSA), which detects a wide variety of prostate cancers. But it cannot distinguish between the life-threatening and the relatively harmless forms of the disease, so is not reliable enough to be used in a national screening programme.

Professor Malcolm Mason, Cancer Research UK's prostate cancer expert based at the University of Cardiff, said: "As a prostate cancer clinician, I have been waiting for years for a test that can define the . I hope that this research brings forward the day when I can say to patients: 'We know that your cancer doesn't need treatment' – a crucial development that could spare thousands of patients from enduring arduous treatment with unpleasant side effects.

"This extremely interesting study provides an important development for , and potentially even reveals a new target for the development of new prostate cancer drugs in the future.

Explore further: Scientists overcome barrier to prostate cancer research

Related Stories

Scientists overcome barrier to prostate cancer research

October 24, 2013
Monash scientists have overcome one of the major barriers to the study and treatment of localised -or organ confined- prostate cancer.

Prostate cancer deaths fall by a fifth in the last 20 years

November 1, 2013
Death rates from prostate cancer have fallen by 20 per cent since the early 1990s according to new figures released by Cancer Research UK.

Prostate cancer test can spot the difference between aggressive and slow-growing tumours

November 5, 2013
A new test may overcome one of the biggest problems in prostate cancer treatment – telling slow-growing tumours from aggressive ones – according to research presented at the National Cancer Research Institute (NCRI) Cancer ...

New early detection test for prostate cancer: Mi-Prostate Score test improves on PSA for predicting cancer

September 26, 2013
More than 1 million men will undergo a prostate biopsy this year, but only about one-fifth of those biopsies will result in a cancer diagnosis.

Novel study charts aggressive prostate cancer

November 18, 2013
Many patients diagnosed with prostate cancer have indolent, slow-growing forms of the disease that are not life-threatening. However, more than 30,000 American men will die from aggressive prostate cancer this year alone. ...

Prostate cancer lifetime risk trebles in 25 years

January 23, 2013
Boys born in 2015 will have almost three times the risk of being diagnosed with prostate cancer at some point during their lives than those born in 1990.

Recommended for you

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.